Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients

NCT06427018 | Recruiting

• 1 other identifier: ShanghaiUTCM-0512
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.

Conditions

Asthma; Protein

Keywords

Asthma; Ezrin; Pip5k1α; Airway smooth muscle

Outcome Measures

Primary Outcomes (2)

• Immunofluorescence results

  IF

  6 months

• Immunohistochemistry results

  IHC

  6 months

Study Arms (2)

Asthma group

No intervention.

Other: No intervention.

Non-asthma group

No intervention.

Other: No intervention.

Interventions

No intervention. OTHER

Observational study with no intervention.

Asthma group; Non-asthma group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Referring to previous validation studies of target proteins in the literature, the sample size required for this validation experiment is related to multiple factors: (1) Selection of genes: mRNA differentially expressed genes will have a 50% probability of differential protein expression. (2) Antibody selection: Commercially available antibodies will be used for immunohistochemical detection of formalin-fixed, paraffin-embedded tissues with a success rate of up to 75%. According to previous validation studies of the target protein, the required samples are 60 in each group, for a total of 120 samples.

You may qualify if:

• Lung tissue samples;
• The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment;
• Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle;
• Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle.

You may not qualify if:

• Paraffin sections of lung tissue from patients who have been diagnosed with COPD;
• Other situations where the researcher deems it inappropriate to participate in this study.

Sponsors & Collaborators

• Yueyang Hospital of Integrated Traditional Chinese and Western Medicine: collaborator
• Shanghai 6th People's Hospital: collaborator
• Xiangya Hospital of Central South University: collaborator
• Baoshan Hospital, Shanghai University of Traditional Chinese Medicine: collaborator
• Shanghai Pulmonary Hospital, Shanghai, China: collaborator
• Lei-Miao Yin: lead

Study Sites (1)

Yueyang Hospital, Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, 200030, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tissue

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Lei-Miao Yin, MD

  Yueyang Hospital, Shanghai University of Traditional Chinese medicine

  STUDY DIRECTOR

• Wei-Wei He, MD

  Shanghai 6th People's Hospital

  STUDY DIRECTOR

• Jun-Tao Feng, MD

  Xiangya Hospital of Central South University

  STUDY DIRECTOR

• Li Li, MD

  Baoshan Hospital, Shanghai University of Traditional Chinese Medicine

  STUDY DIRECTOR

• Xiao-Ling Xu, MD

  Shanghai Pulmonary Hospital, Tongji University

  STUDY DIRECTOR

Central Study Contacts

Lei-Miao Yin, MD

CONTACT

86 21 54592134; collegeylm@shutcm.edu.cn

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: May 19, 2024
• First Posted: May 23, 2024
• Study Start: May 28, 2024
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: January 14, 2026

Record last verified: 2026-01

Locations

CN (1)